
Industry-leading weight loss without medications
Navigating type 2 diabetes and obesity in the world of GLP-1s
Weight loss medication use and costs are skyrocketing. Virta can help.
GLP-1 use, both on- and off-label, has led to surging Rx costs for payers, and even medication shortages for people who truly need them.
GLP-1s are effective but expensive and still require lifestyle changes
Traditional diet and exercise programs are unsuccessful in helping maintain weight loss
Costs are rising 2-4x for GLP-1 drug class alone
A better way to navigate GLP-1 costs and utilization
Current GLP-1 strategies fall into three categories: easy access, gatekeeper with prior authorization and step therapy, and combo therapy with traditional diet and exercise.
Virta offers new options to manage GLP-1 utilization while protecting access for those who need it.
An alternative to GLP-1s
A sustainable GLP-1 offramp
Comparable weight loss to GLP-1s at a fraction of the cost
Virta is a leading virtual clinic that reverses type 2 diabetes, obesity, and prediabetes. Our members lose weight—while reducing dependence on GLP-1s and other medications—and experience long-lasting results at a fraction of the cost of pharmaceutical or surgical treatments.
12%
A proven approach for deprescribing GLP-1s
Virta aims to deprescribe diabetes and obesity medications (including GLP-1s) for everyone in whom it is safe to do so
- Health coaches support members in making nutritional changes.
- Members lose weight and feel better.
- Virta providers deprescribe GLP-1s and other medications based on rigorous clinical protocols.
- Members sustain weight loss progress.
4 in 5 executives are significantly concerned about GLP-1 growth
Find out why Chief Medical Officers, Chief Pharmacy Officers and actuarial leaders are significantly concerned about GLP-1 utilization and cost growth and why they expect this crisis to last the rest of the decade.
Read the report
Life-changing weight loss that lasts
Ready to learn more?
- Hallberg SJ et al. Diabetes Therapy. 2018;9(2):583-612 and Bhanpuri NH et al. Cardiovasc Diabetol. 2018; 17:56.